Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor

被引：3
|
作者：
Iyer, Chandrasekar
Li, Binghui
Stewart, Trent R.
Wang, Tao
Capen, Andrew
Cavitt, Rachel
Anderson, Bryan D.
Bocchinfuso, Wayne
Zhao, Gaiying
Rodriguez, Michael J.
Carballares, Santiago
Cooke, Andrew
Bondi, Robert
Burns, Lee
Kelamangalath, Lakshmi
Wallace, Ross
Kolakowski, Gabrielle
Henry, James R.
Si, Chong
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B115
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B115
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Discovery and characterization of ZL-2201, a potent, highly-selective, and orally bioavailable small-molecule DNA-PK inhibitor
    Lal, Shruti
    Sun, Bee-Chun
    Chen, Yuping
    Huang, Tom
    Bhola, Neil
    Morton, Vivian
    Chen, Kevin
    Xia, Shanghua
    Zhang, Haoyu
    Ye, Qiuping
    Veiby, Petter
    Bellovin, David I.
    Ji, Yuhua
    CANCER RESEARCH, 2022, 82 (12)
  • [42] Selective epithelial activation of KRAS G12D mutation drives ductal pancreatic neoplasia in pigs
    Jara, Carlos P.
    Al-Gahmi, Al-Murtadha
    Le, Binh
    Carlson, Mark A.
    CANCER RESEARCH, 2024, 84 (02)
  • [43] Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor
    Yamakawa, Hiroko
    Mizutani, Akio
    Arikawa, Yasuyoshi
    Ebara, Shunsuke
    Satoh, Yoshihiko
    Morishita, Daisuke
    CANCER SCIENCE, 2023, 114 : 831 - 831
  • [44] Pharmacodynamic response of CH4987655 (RO4987655), a potent and selective orally bioavailable MEK inhibitor, in preclinical models
    Yoshimura, Yasushi
    Ishii, Nobuya
    Sakamoto, Hiroshi
    Miura, Takaaki
    Isshiki, Yoshiaki
    Ishikawa, Yuji
    Miwa, Masanori
    Shimma, Nobuo
    Okabe, Hisafumi
    Aoki, Yuko
    CANCER RESEARCH, 2009, 69
  • [45] Pharmacological characterization of the selective, orally bioavailable, potent mTORC1/2 inhibitor PQR620
    Beaufils, Florent
    Rageot, Denise
    Melone, Anna
    Sele, Alexander
    Lang, Marc
    Mestan, Juergen
    Ettlin, Robert A.
    Hillmann, Petra
    Cmiljanovic, Vladimir
    Walter, Carolin
    Singer, Elisabeth
    Nguyen, Hoa H. P.
    Hebeisen, Paul
    Fabbro, Dorian
    Wymann, Matthias P.
    CANCER RESEARCH, 2016, 76
  • [46] LY2969822: Pharmacological Characterization of an Orally Bioavailable Prodrug for a Potent, Selective mGlu2/3 Receptor Agonist
    McKinzie, D. L.
    Johnson, B. J.
    Knitowski, K.
    Shaw, D.
    Rorick-Kehn, L.
    Katner, J.
    Perry, K.
    Swanson, S.
    Catlow, J.
    Johnson, M. P.
    Prieto, L.
    Beadle, C.
    Monn, J. A.
    CURRENT NEUROPHARMACOLOGY, 2014, 12 : 40 - 40
  • [47] Preclinical Development of Safe and Effective T Cell Receptors Specific for Mutant KRAS G12V and G12D Peptides
    Martinov, Tijana
    Perret, Rachel
    Mureli, Shwetha
    McCurdy, Clara
    Vazquez, Angie
    Lee, Jihoon
    Webb, Jessica
    Black, Cheryl
    Parsons, James
    Francis, Joshua
    Lam, Hubert
    Shapiro, Gary
    Vincent, Loic
    Chapuis, Aude
    Schmitt, Thomas
    Greenberg, Philip
    MOLECULAR THERAPY, 2022, 30 (04) : 55 - 55
  • [48] BI KRASmulti, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRAS G12V-driven preclinical models
    Peng, David H.
    Tedeschi, Antonio
    Herdeis, Lorenz
    Savarese, Fabio
    Rocchetti, Francesca
    Johannes, Popow
    Huber, Heinrich J.
    Melillo, Nicola
    Dickinson, Jake
    Mistry, Hitesh B.
    Wilding, Birgit
    Treu, Matthias
    Fuchs, Julian
    Broker, Joachim
    Wunberg, Tobias
    Schischlik, Fiorella
    Lipp, Jesse
    Ramamoorthy, Vandhana
    Daniele, Joseph R.
    Kopetz, Scott
    Kim, Michael
    Gibbons, Don L.
    Vellano, Christopher P.
    Marszalek, Joseph R.
    Heffernan, Timothy P.
    McConnell, Darryl
    Pearson, Mark
    Kraut, Norbert
    Rudolph, Dorothea
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [49] Exploring the switch II pocket of KRAS(G12D) with mutant-selective monobody inhibitors
    Hattori, Takamitsu
    Akkapeddi, Padma
    Khan, Imran
    Koide, Akiko
    Glasser, Eliezra
    Ketavarapu, Gayatri
    Whaby, Michael
    Zuberi, Mariyam
    Teng, Kai Wen
    Lefler, Julia
    Maso, Lorenzo
    Bang, Injin
    Ostrowski, Michael C.
    O'Bryan, John P.
    Koide, Shohei
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [50] Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor
    Yu, Yiyun
    Jang, Miyeon
    Miyashiro, Julie
    Clark, Richard F.
    Zhu, Gui-Dong
    Gong, Jane
    Dai, Yujia
    Frey, Robin R.
    Penning, Thomas D.
    Kim, Hadong
    Lee, Hyung Ki
    Kim, Jin Kwan
    Ryu, Ki Moon
    Park, Seong Jin
    Yoon, Taeyoung
    Li, Tao
    Kurnick, Matthew D.
    Kapecki, Nicolas J.
    Li, Leiming
    Gorman, Jacob V.
    Montgomery, Debra A.
    Manaves, Vlasios
    Bromberg, Kenneth D.
    Doktor, Stella Z.
    Thakur, Ashish
    Wang, Jin
    Smith, Heath A.
    Buchanan, Fritz G.
    Ferguson, Debra C.
    Torrent, Maricel
    Jakob, Clarissa G.
    Qiu, Wei
    Upadhyay, Anup K.
    Martin, Ruth L.
    Lai, Albert
    Michaelides, Michael R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (19) : 17000 - 17032
12345